{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:32:46Z","timestamp":1761921166120},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,23]]},"DOI":"10.7759\/cureus.43984","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:50:34Z","timestamp":1692805834000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-\u00df Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Kamran","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonas","family":"Tamene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shefali P","family":"Mody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiser O","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogamba M","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshwar","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivana","family":"Ramphall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hsr.2022.100039","article-title":"Aducanumab: a new hope in alzheimer's disease","volume":"4","author":"Ali R","year":"2022","unstructured":"Ali R, Gupta GD, Chawla PA. Aducanumab: a new hope in alzheimer's disease. Health Sci Rev. 2022, 4:100039. 10.1016\/j.hsr.2022.100039","journal-title":"Health Sci Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2015.1002469","article-title":"Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities","volume":"15","author":"Reitz C","year":"2015","unstructured":"Reitz C. Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn. 2015, 15:339-48. 10.1586\/14737159.2015.1002469","journal-title":"Expert Rev Mol Diagn"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The Alzheimer's disease clinical spectrum: diagnosis and management","volume":"103","author":"Atri A","year":"2019","unstructured":"Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019, 103:263-93. 10.1016\/j.mcna.2018.10.009","journal-title":"Med Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane CA","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018, 25:59-70. 10.1111\/ene.13439","journal-title":"Eur J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease","volume":"18","author":"Khan S","year":"2020","unstructured":"Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease. Curr Neuropharmacol. 2020, 18:1106-25. 10.2174\/1570159X18666200528142429","journal-title":"Curr Neuropharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review","volume":"72","author":"Jeremic D","year":"2021","unstructured":"Jeremic D, Jim\u00e9nez-D\u00edaz L, Navarro-L\u00f3pez JD. Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review. Ageing Res Rev. 2021, 72:101496. 10.1016\/j.arr.2021.101496","journal-title":"Ageing Res Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2015.03.012","article-title":"Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein","volume":"33","author":"Folch J","year":"2018","unstructured":"Folch J, Ettcheto M, Petrov D, et al.. Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein. Neurologia (Engl Ed). 2018, 33:47-58. 10.1016\/j.nrl.2015.03.012","journal-title":"Neurologia (Engl Ed)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14033","article-title":"Blood pressure variability and the risk of dementia: a nationwide cohort study","volume":"75","author":"Yoo JE","year":"2020","unstructured":"Yoo JE, Shin DW, Han K, et al.. Blood pressure variability and the risk of dementia: a nationwide cohort study. Hypertension. 2020, 75:982-90. 10.1161\/HYPERTENSIONAHA.119.14033","journal-title":"Hypertension"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas SA","year":"2007","unstructured":"Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007, 13:9-20. 10.18553\/jmcp.2007.13.s8-b.9","journal-title":"J Manag Care Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00263-5","article-title":"Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"20","author":"Kehoe PG","year":"2021","unstructured":"Kehoe PG, Turner N, Howden B, et al.. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2021, 20:895-906. 10.1016\/S1474-4422(21)00263-5","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101612","article-title":"Targeting brain renin-angiotensin system for the prevention and treatment of Alzheimer's disease: past, present and future","volume":"77","author":"Gouveia F","year":"2022","unstructured":"Gouveia F, Camins A, Ettcheto M, Bicker J, Falc\u00e3o A, Cruz MT, Fortuna A. Targeting brain renin-angiotensin system for the prevention and treatment of Alzheimer's disease: past, present and future. Ageing Res Rev. 2022, 77:101612. 10.1016\/j.arr.2022.101612","journal-title":"Ageing Res Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2017.04.001","article-title":"Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice","volume":"64","author":"Torika N","year":"2017","unstructured":"Torika N, Asraf K, Cohen H, Fleisher-Berkovich S. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice. Brain Behav Immun. 2017, 64:80-90. 10.1016\/j.bbi.2017.04.001","journal-title":"Brain Behav Immun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00723-6","article-title":"Intranasal Losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats","volume":"16","author":"Drews HJ","year":"2019","unstructured":"Drews HJ, Yenkoyan K, Lourhmati A, et al.. Intranasal Losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats. Neurotherapeutics. 2019, 16:725-40. 10.1007\/s13311-019-00723-6","journal-title":"Neurotherapeutics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020166","article-title":"Losartan improves memory, neurogenesis and cell motility in transgenic Alzheimer's mice","volume":"14","author":"Drews HJ","year":"2021","unstructured":"Drews HJ, Klein R, Lourhmati A, et al.. Losartan improves memory, neurogenesis and cell motility in transgenic Alzheimer's mice. Pharmaceuticals (Basel). 2021, 14:10.3390\/ph14020166","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12802","article-title":"Candesartan ameliorates brain inflammation associated with Alzheimer's disease","volume":"24","author":"Torika N","year":"2018","unstructured":"Torika N, Asraf K, Apte RN, Fleisher-Berkovich S. Candesartan ameliorates brain inflammation associated with Alzheimer's disease. CNS Neurosci Ther. 2018, 24:231-42. 10.1111\/cns.12802","journal-title":"CNS Neurosci Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging","volume":"8","author":"Lowe SL","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, et al.. Donanemab (LY3002813) phase 1b study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimers Dis. 2021, 8:414-24. 10.14283\/jpad.2021.56","journal-title":"J Prev Alzheimers Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun MA","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al.. Donanemab in early Alzheimer's disease. N Engl J Med. 2021, 384:1691-704. 10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after Donanemab treatment with Tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin S","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, et al.. Association of amyloid reduction after Donanemab treatment with Tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022, 79:1015-24. 10.1001\/jamaneurol.2022.2793","journal-title":"JAMA Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson CJ","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al.. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021, 13:80. 10.1186\/s13195-021-00813-8","journal-title":"Alzheimers Res Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade E","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, et al.. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022, 14:191. 10.1186\/s13195-022-01124-2","journal-title":"Alzheimers Res Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody RS","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, et al.. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014, 370:311-21. 10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig LS","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, et al.. Trial of Solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018, 378:321-30. 10.1056\/NEJMoa1705971","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein S","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al.. Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022, 9:197-210. 10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac270","article-title":"Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease","volume":"4","author":"Hajjar I","year":"2022","unstructured":"Hajjar I, Okafor M, Wan L, et al.. Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease. Brain Commun. 2022, 4:fcac270. 10.1093\/braincomms\/fcac270","journal-title":"Brain Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1137197","article-title":"Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: a nationwide population-based cohort study","volume":"15","author":"Lee HW","year":"2023","unstructured":"Lee HW, Kim S, Jo Y, Kim Y, Ye BS, Yu YM. Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: a nationwide population-based cohort study. Front Aging Neurosci. 2023, 15:1137197. 10.3389\/fnagi.2023.1137197","journal-title":"Front Aging Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab treatment With exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary snalysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo MJ","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, et al.. Association of Donanemab treatment With exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary snalysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022, 79:1250-9. 10.1001\/jamaneurol.2022.3392","journal-title":"JAMA Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2020.12.011","article-title":"Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers","volume":"100","author":"Ouk M","year":"2021","unstructured":"Ouk M, Wu CY, Rabin JS, et al.. Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiol Aging. 2021, 100:22-31. 10.1016\/j.neurobiolaging.2020.12.011","journal-title":"Neurobiol Aging"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/1533317517707288","article-title":"Elevated plasma A\u03b242 in cognitively impaired individuals taking ACE inhibitor antihypertensives","volume":"32","author":"Regenold WT","year":"2017","unstructured":"Regenold WT, Blumenthal JB, Loreck DJ, Mordecai KL, Scarinzi G, Doddi SR, Adler L. Elevated plasma A\u03b242 in cognitively impaired individuals taking ACE inhibitor antihypertensives. Am J Alzheimers Dis Other Demen. 2017, 32:347-52. 10.1177\/1533317517707288","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.01.002","article-title":"Longitudinal decline in mild-to-moderate Alzheimer's disease: analyses of placebo data from clinical trials","volume":"12","author":"Thomas RG","year":"2016","unstructured":"Thomas RG, Albert M, Petersen RC, Aisen PS. Longitudinal decline in mild-to-moderate Alzheimer's disease: analyses of placebo data from clinical trials. Alzheimers Dement. 2016, 12:598-603. 10.1016\/j.jalz.2016.01.002","journal-title":"Alzheimers Dement"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/175756-comparative-study-of-safety-and-efficacy-of-angiotensin-receptor-blockers-and-anti-amyloid--monoclonal-antibodies-for-the-treatment-of-alzheimers-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:08Z","timestamp":1707508508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/175756-comparative-study-of-safety-and-efficacy-of-angiotensin-receptor-blockers-and-anti-amyloid--monoclonal-antibodies-for-the-treatment-of-alzheimers-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.43984","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}